BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34939467)

  • 1. Next Generation Sequencing Reveals Pathogenic and Actionable Genetic Alterations of Soft Tissue Sarcoma in Chinese Patients: A Single Center Experience.
    Jin G; Wang C; Jia D; Qian W; Yin C; Wang D; Yang Q; Li T; Zheng A
    Technol Cancer Res Treat; 2021; 20():15330338211068964. PubMed ID: 34939467
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
    Jour G; Scarborough JD; Jones RL; Loggers E; Pollack SM; Pritchard CC; Hoch BL
    Hum Pathol; 2014 Aug; 45(8):1563-71. PubMed ID: 24908143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
    Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
    Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
    Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical utility of next-generation sequencing for bone and soft tissue sarcoma.
    Gusho CA; Weiss MC; Lee L; Gitelis S; Blank AT; Wang D; Batus M
    Acta Oncol; 2022 Jan; 61(1):38-44. PubMed ID: 34686105
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.
    Gan M; Zhang C; Qiu L; Wang Y; Bao H; Yu R; Liu R; Wu X; Shao Y; Hou P; Fei Z
    Cancer Med; 2022 Nov; 11(21):4070-4078. PubMed ID: 35586877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
    Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA; Bilen MA
    Oncologist; 2022 Jun; 27(6):462-468. PubMed ID: 35462410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Profiling and Clinical Outcomes of Targeted Therapies in Adult Patients with Soft Tissue Sarcomas.
    Kokkali S; Georgaki E; Mandrakis G; Valverde C; Theocharis S
    Cells; 2023 Nov; 12(22):. PubMed ID: 37998367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
    Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
    Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.
    Zheng B; Qu Y; Wang J; Shi Y; Yan W
    Cancer Genomics Proteomics; 2019; 16(3):221-228. PubMed ID: 31018952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
    Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
    J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
    Andersson C; Fagman H; Hansson M; Enlund F
    Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel fusion sarcomas including targetable NTRK and ALK.
    Chen T; Wang Y; Goetz L; Corey Z; Dougher MC; Smith JD; Fox EJ; Freiberg AS; Flemming D; Fanburg-Smith JC
    Ann Diagn Pathol; 2021 Oct; 54():151800. PubMed ID: 34464935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.